



Published in final edited form as:

*Nat Chem Biol.* 2018 February ; 14(2): 135–141. doi:10.1038/nchembio.2534.

## Inhibiting mitochondrial phosphate transport as an unexploited antifungal strategy

Catherine A. McLellan<sup>1,2,8</sup>, Benjamin M. Vincent<sup>1,3,8</sup>, Norma V. Solis<sup>4</sup>, Alex K. Lancaster<sup>1</sup>, Lucas B. Sullivan<sup>5</sup>, Cathy L. Hartland<sup>6</sup>, Willmen Youngsaye<sup>6</sup>, Scott G. Filler<sup>4,7</sup>, Luke Whitesell<sup>1,\*</sup>, and Susan Lindquist<sup>1,2</sup>

<sup>1</sup>Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, 02142, USA

<sup>2</sup>Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA

<sup>3</sup>Microbiology Graduate Program, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA

<sup>4</sup>Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA

<sup>5</sup>Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA

<sup>6</sup>Chemical Biology Platform and Probe Development Center, Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA

<sup>7</sup>David Geffen School of Medicine at UCLA, Los Angeles, California USA

### Abstract

The development of effective antifungal therapeutics remains a formidable challenge due to the close evolutionary relationship between humans and fungi. Mitochondrial function may present an

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\***Corresponding Author Statement:** L.J.W. is the corresponding author.

<sup>8</sup>**Equal Contributions Statement** C.A.M. and B.M.V. contributed equally to this work.

<sup>9</sup>Deceased

#### Current Addresses

Benjamin M. Vincent, Yumanity Therapeutics Cambridge, MA, USA

Alex K. Lancaster, Ronin Institute, Montclair, N.J., USA

Cathy L. Hartland, Center for Developmental Therapeutics, Broad Institute, Cambridge, MA, USA

Willmen Youngsaye, Ariad Pharmaceuticals, Cambridge, MA, USA

#### Author contributions

L.W., S.L., B.M.V. and C.A.M. conceived and designed the study. C.A.M., B.M.V. and L.W. performed microbiological, genetic, biochemical and metabolic studies. B.M.V. and A.K.L. analyzed whole fungal genome sequencing data. C.L.H. performed the primary and follow-up screening work that led to the identification of ML316. W.Y. provided chemistry advice and synthesized ML316. L.B.S. performed the oxygen consumption experiments. N.V.S., S.G.F. and L.W. designed, performed and analyzed animal experiments.

#### Competing Financial Interest Statement

B.M.V., S.L., L.W., and W.Y. are inventors on a patent application (published as US20150259298) relating to compounds described in this work and uses thereof. S.G.F. is a co-founder and shareholder in NovaDigm Therapeutics, Inc., a company focused on vaccine development against *Candida*.

exploitable vulnerability due to its differential utilization in fungi and its pivotal roles in fungal morphogenesis, virulence, and drug resistance already demonstrated by others. We now report mechanistic characterization of ML316, a thiohydantoin which kills drug-resistant *Candida* species at nanomolar concentrations through fungal-selective inhibition of the mitochondrial phosphate carrier Mir1. We established ML316 as the first Mir1 inhibitor using genetic, biochemical, and metabolomic approaches. Inhibition of Mir1 by ML316 in respiring yeast diminished mitochondrial oxygen consumption resulting in an unusual metabolic catastrophe marked by citrate accumulation, and death. In a mouse model of azole-resistant oropharyngeal candidiasis, ML316 reduced fungal burden and enhanced azole activity. Targeting Mir1 could provide a new, much needed therapeutic strategy to address the rapidly rising burden of drug-resistant fungal infection.

## Introduction

A health crisis from fungal diseases is looming due to the marked increase of at-risk populations and the rising prevalence of drug resistance. The limited number of antifungal classes available and the unacceptably high mortality rate from invasive infections make the need for new antifungals dire. Fungi are eukaryotes, and as such share many conserved proteins and processes with humans which presents a daunting challenge to developing new, mechanistically distinct antifungals<sup>1</sup>. With this challenge in mind, we executed a high throughput phenotypic screen for compounds that could reverse resistance to the widely used antifungal fluconazole in a clinical isolate of *Candida albicans* (National Center for Biotechnology Information, PubChem BioAssay Database; AID=2007, <https://pubchem.ncbi.nlm.nih.gov/bioassay/2007>)<sup>2</sup>. A particularly intriguing hit to emerge from this screen was a thiohydantoin (PubChem CID 3889161) which exerted potent antifungal activity as a single agent with no apparent toxicity to mammalian cells. Substructure searches did not reveal any assay interference alerts<sup>3</sup>. Its thiohydantoin core is present in enzalutamide, an androgen-receptor antagonist used in the treatment of prostate cancer<sup>4</sup>. Follow-up synthesis and testing of 51 analogs in a limited SAR study yielded the designated probe compound ML316, a *para*-fluoro phenyl derivative with improved potency and selectivity (<https://www.ncbi.nlm.nih.gov/books/NBK143544/>).

The promising attributes of ML316 encouraged further investigation and we now report discovery of its molecular mechanism of action through a combination of genetic and biochemical approaches. This drug-like compound, distinct from all previously characterized mitochondrial poisons, selectively inhibits Mir1, the major mitochondrial phosphate carrier protein (P<sub>i</sub>C). Mir1 transports inorganic phosphate into the inner matrix of fungal mitochondria where it is utilized by ATP synthase to generate ATP. Guided by this insight, we used the compound as a probe to investigate the surprising biological consequences of disrupting fungal respiration at its terminal step and to explore the translational therapeutic potential of inhibiting Mir1 in culture and in mice.

## Results

### ML316 is fungicidal under respiratory conditions

As previously reported, ML316 (**1**) exhibited more potent antifungal activity against azole-resistant *C. albicans* than our original screen hit (**2**) while substitution of oxygen for sulfur in the thiohydantoin core (**3**) greatly diminished activity (Fig. 1a). Although ML316 was equally effective at inhibiting the growth of wild-type *C. albicans* in media with either glucose or non-fermentable glycerol as the sole carbon source, it only inhibited growth of the model fungal organism *Saccharomyces cerevisiae* when it was grown in glycerol to enforce respiration (Fig. 1b). *C. albicans* is a facultative aerobe and respire when oxygen is present regardless of the carbon source. *S. cerevisiae* on the other hand solely ferments glucose even in the presence of abundant oxygen<sup>5</sup>. A distantly related *Candida* species, *C. glabrata*, also shuts off respiration in the presence of glucose. As demonstrated in the probe report, toxicity in this fungal species was similarly dependent on growth in glycerol, confirming a requirement for respiration in ML316 toxicity and suggesting a mode of action targeting some aspect of mitochondrial function.

In addition to effectively inhibiting wild-type *Candida* growth, ML316 exhibited potent antifungal activity against the moderately-azole-resistant *C. albicans* strain CaCi-2<sup>6</sup> as a single-agent (MIC 0.05 µg/mL) (Fig. 1c). Despite its clinically acquired azole-resistance, when CaCi-2 was simultaneously exposed to ML316 and a threshold concentration of fluconazole, its potency increased greatly (Fig. 1c). To better characterize the antifungal activity of the combination, we performed standard checkerboard analysis<sup>7</sup>. Interaction of the compounds was found neither formally synergistic nor antagonistic in this strain (Supplementary Fig. 1).

The activity of ML316 against CaCi-2 prompted us to investigate its effects against a wider range of fluconazole-resistant *Candida* strains (Fig. 1d). For these experiments, a series of clinical isolates cultured from a single HIV-infected patient over a 2-year period was assessed<sup>6,8</sup>. ML316 remained very active (MIC 0.5 µg/mL) as a single agent against all the isolates tested including the most fluconazole-resistant strain in the series, CaCi-17 (fluconazole MIC >128 µg/mL). ML316 retained activity against this strain despite the fact that a major contributor to the high-level azole-resistance of CaCi-17 is up-regulation of both the ABC and MDR efflux pump systems<sup>6</sup>, which confer pleiotropic resistance to many small molecules by limiting their intracellular accumulation. To confirm that activity was not limited to one patient series, we tested other azole-resistant strains<sup>9</sup> and found that they also remained sensitive to ML316 (Supplementary Table 1). Four strains of the emerging pathogen *C. auris*, a cause of increasing alarm because of its frequent resistance to known antifungals and potential for epidemic spread in hospital settings were also tested<sup>10</sup>. They were all sensitive to ML316 as well (Supplementary Table 1).

Because respiration was required for toxicity in fungi, we evaluated the selectivity of ML316 using human cells grown under conditions enforcing respiration. As expected, a classical inhibitor of respiration, antimycin A, was highly toxic to both 293T (kidney-derived) and HepG2 (liver-derived) cells<sup>11</sup>. Under these same conditions, however, ML316 had no effect on the growth and survival of these cells (Fig. 1e). To rule out potential effects of serum on

the bio-availability or stability of ML316, experiments were repeated under serum-free growth conditions where ML316 remained non-toxic to respiring human cells (Supplementary Fig. 2).

Many widely used antifungals are cytostatic, stopping the growth of yeast but not killing them. To characterize the nature of ML316's antifungal effects, we performed clonogenic survival assays using the CaCi-2 strain and a broad range of ML316 concentrations (Fig. 1f). Fungicidal amphotericin and fungistatic fluconazole served as controls (Supplementary Fig. 3). At 24 hours, all compounds inhibited growth as measured by OD<sup>600</sup>. Subsequent plating and re-growth in the absence of compound, however, demonstrated that yeast survived at all concentrations of fluconazole tested. In contrast, ML316 and amphotericin were cytotoxic at concentrations greater than 1.25  $\mu$ M at 30°C. When incubation temperature was increased to human host-range (37°C), ML316 sensitivity was increased by approximately 10-fold. Such potent, environmentally-sensitive fungicidal activity of ML316 led us to move beyond phenotypic characterization and pursue the compound's mode of action and proximal target at the molecular level.

### Mitochondrial Phosphate Carrier Mutation Confers Resistance

We began investigating the molecular basis of ML316 action by selecting for suppressor mutants in *Candida* that could grow in the presence of ML316 (5 $\mu$ M) under conditions requiring respiration (glycerol as sole carbon source). Mutants emerged at a low rate (~1 in 50 million cells). Genome sequencing of three ML316-resistant mutants from independent selections revealed that they all carried an identical heterozygous mutation (causing the amino acid substitution N184T) in one allele of the *MIR1* gene which encodes the major mitochondrial P<sub>i</sub>C (Supplementary Fig.4a). The Mir1 protein is localized to the inner membrane of mitochondria and carries phosphate into the matrix. No selective small molecule inhibitors of this protein have been identified. Only low-affinity, non-selective, thiol-reactive agents (such as mersalyl and *N*-ethylmaleimide) have been used to probe its biochemical activity. In genetic experiments, Mir1 is required for respiration in *S. cerevisiae*, but not for its fermentative growth. Requirements for it have not been studied in *C. albicans* or other fungal pathogens<sup>12-16</sup>. When aligned with its homologs in other species, the asparagine at position 184 of the Mir1 expressed in *Saccharomyces* and *Candida* species was found to be replaced by threonine, the very same N184T resistance-conferring alteration we found in our suppressor selection experiments. All organisms sensitive to ML316 tested so far have asparagine at this position, while all species with threonine have been found resistant, including the human mitochondrial P<sub>i</sub>C, *SLC25A3* (Supplementary Fig. 4b).

### Genetic confirmation of Mir1 as target of ML316

To provide further genetic support for Mir1 as the proximal protein target responsible for ML316 action, *C. albicans* strains were constructed that differed in *MIR1* copy number or mutation status. Deletion of one copy of the *MIR1* gene in this diploid organism caused a 2-fold decrease in the MIC for ML316, supporting it as the target of this compound on the principle of induced haplo-insufficiency<sup>17</sup>. Integration into the genome of an additional wild-type copy of the *MIR1* gene resulted in an approximately 2-fold decrease in sensitivity to ML316. When a mutant copy of *MIR1* encoding the suppressor found in our screen

(*mir1R*) was introduced, resistance to ML316 increased 512-fold (Fig. 2a). Manipulation of gene copy number and introduction of the suppressor mutant in *S. cerevisiae* grown in glycerol-containing medium produced changes in ML316 sensitivity similar to those demonstrated in *Candida* (Supplementary Fig. 4c).

Two functionally redundant mitochondrial P<sub>i</sub>Cs have been described in *S. cerevisiae*, Mir1 and Pic2. *C. albicans* also contains a *PIC2* ortholog, C2\_09590C. In *S. cerevisiae*, the sequence of Pic2 is 40% identical to Mir1 and it has the single amino acid change (N184T) encoded by *mir1R*<sup>18</sup>. *S. cerevisiae* strains were constructed with complete deletion of either *MIR1* or *PIC2* to determine if ML316 inhibition is specific to Mir1. All strains grew identically in glucose-containing medium supplemented with either vehicle (DMSO) or ML316 (500 nM) (Fig. 2b). Strains containing a deletion of *MIR1* cannot grow in glycerol medium which enforces respiration. In galactose, which can be fermented, but requires both respiration and glycolytic fermentation for optimal growth, addition of ML316 decreased the growth of wild-type yeast (Fig. 2c). Reduction in growth phenocopied the reduction seen when *MIR1* is deleted, suggesting Mir1 as the target responsible for ML316-induced growth inhibition. ML316-treated  $\Delta$ *mir1* yeast grew the same as  $\Delta$ *mir1* treated with vehicle, further supporting this conclusion. Growth of our  $\Delta$ *pic2* strain in galactose was identical to that of wild-type yeast. In the presence of ML316, however, growth reduction was even greater than in a *PIC2* wild-type background. We conclude that *S. cerevisiae* Pic2 is insensitive to ML316 and can partially compensate for loss of Mir1 function during growth in galactose.

### Functional confirmation of Mir1 as target of ML316

We used a classical assay of mitochondrial phosphate import, the swelling of isolated mitochondria upon incubation in hypertonic ammonium phosphate, to examine the effect of ML316 on uptake of inorganic phosphate into fungal mitochondria (Fig. 3a). In this assay, the optical density (OD) of isolated mitochondria preparations was monitored as a measure of organelle integrity. Freshly prepared mitochondria were suspended in varying hypertonic ammonium salt solutions. Mitochondria are freely permeable to ammonium cation. If its corresponding anion can also enter the mitochondria, they swell and burst, resulting in a rapid decrease in optical density of the resultant suspension<sup>15</sup>. As anticipated, incubation of mitochondria in ammonium phosphate buffer resulted in a rapid decline in OD (Fig. 3a, upper left panel; blue trace). Phosphate, however, is known to require a carrier function provided by Mir1 to access the matrix and burst mitochondria<sup>15</sup>. Strongly supporting its ability to directly impair Mir1 function, ML316 prevented the OD decline induced by phosphate (purple trace). The Mir1-dependence of this effect was confirmed by testing mitochondria isolated from a strain expressing the ML316-resistant N184T mutant encoded by *mir1R*. Phosphate-induced declines in OD were not prevented by ML316 in this background (Fig. 3a, upper right panel). As further specificity controls, we tested effects of ML316 on permeability to other anions. We found that loss of mitochondrial integrity caused by acetate, which enters rapidly in a Mir1-independent manner, was not inhibited by ML316 in either genetic background while integrity in chloride, which is unable to enter intact mitochondria, was likewise unaffected by ML316 (Fig. 3a, middle panels).

### Role of respiration in ML316-induced toxicity

To directly measure the effect of ML316 on respiration in whole cells, we measured oxygen consumption in *C. albicans* following 10 minute treatment with ML316 (10  $\mu$ M) or DMSO (Fig. 3b, lower panel). Antimycin was then added to determine the non-mitochondrial oxygen consumption rate, which was subtracted from the initial rate to yield mitochondrial oxygen consumption rate (MOC). Our strain with one extra copy of *MIR1* showed a significant decrease in MOC upon ML316 treatment. The strain supplemented with a mutant drug-resistant allele (*mir1R*) displayed a lower, but not statistically significant decrease (*MIR1*/DMSO versus *mir1R*/DMSO) in basal MOC. Importantly, this MOC did not change significantly with ML316 treatment. These results confirm that inhibition of Mir1 by ML316 impairs mitochondrial respiration. They also suggest that the drug-resistant mutant does not function as well as the wild-type isoform in *Candida* under conditions that require respiration.

To better understand why ML316 was toxic to *C. albicans* even when grown on fermentable carbon sources, we selected for resistant colonies on medium containing ML316 (5  $\mu$ M) and 2% glucose. Potential resistance-conferring mutations were identified by whole-genome sequencing. Slow-growing colonies emerged at a relatively high frequency ( $10^{-5}$ ). Sequencing of one of these colonies revealed deletions in the mitochondrially-encoded gene *COX1*. This gene encodes a core enzymatic subunit of cytochrome C oxidase (Complex IV of the electron transport chain in yeast)<sup>19</sup>. Its activity is required for cellular respiration and growth on non-fermentable carbon sources as demonstrated by the inability of the *cox1* mutant to grow on glycerol-containing media (Fig. 4a). The finding indicates that interrupting electron transport upstream of ATP synthase can rescue the lethality of depleting mitochondrial phosphate with ML316. Ongoing respiration, even when growing in glucose, appears to sensitize *Candida* to ML316. To determine whether this effect was restricted to the *COX1* gene, we evaluated *cox4 $\Delta$  $\Delta$*  (nuclearly-encoded Complex IV member) and *rip1 $\Delta$  $\Delta$*  (nuclearly-encoded Complex III member) deletion mutants. As a chemical biological complement, we also tested INZ-5, a recently described selective inhibitor of the bc1 complex (Supplementary Fig. 5)<sup>2</sup>. All these interventions which interrupt electron transport conferred resistance to ML316. Importantly, the ML316-resistant *cox1* mutant was extremely sensitive to fluconazole, even when selected in a strain background with established fluconazole-resistance (Fig. 4a). This finding is consistent with a previously reported requirement for mitochondrial respiration in azole tolerance<sup>2,20</sup>. Moreover, respiration-defective mutants grow slowly and exhibit reduced virulence<sup>2</sup>. Although resistance to ML316 was achieved under high glucose conditions *in vitro* by eliminating oxidative phosphorylation, this resistance strategy is unlikely to pose a problem *in vivo* where the niches occupied by fungi are poor in fermentable substrates and co-administration of azole would greatly disfavor it.

### A marked increase in citrate accompanies ML316 toxicity

To better understand the metabolic effects of ML316 in fungi, we compared compound-treated vs. control-treated yeast by LC/MS-based global polar metabolite profiling. Extracts were prepared from *C. albicans* growing in glucose that had been treated for 90 minutes with ML316, with electron transport chain poisons (rotenone, antimycin, and potassium cyanide),

or with the uncouplers 2,4-dinitrophenol (2,4-DNP) and carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP). As expected, blocking electron transport altered the levels of a wide range of polar metabolites. Succinate and citrate showed the largest changes, reaching a threshold of greater than 4-fold ( $\log_2$  change > 2) (Supplementary Table 2). Succinate levels decreased  $4.25 \pm 0.6$ -fold in two independent experiments. A decrease in succinate appeared to be common to all the compounds tested with FCCP driving the greatest alteration ( $5.5 \pm 1$ -fold reduction). Unique to ML316, however, we found a dramatic (>7-fold) increase in levels of citrate, a central player in mitochondrial metabolism (Fig. 4b). Electron transport chain inhibitors caused only a mild (<2-fold) induction in citrate levels, and uncouplers had minimal effect. In follow-up experiments focused on citrate alterations, levels rose 3-fold within 30 minutes of ML316 treatment, and >12-fold at 60 minutes post treatment (Fig. 4b). In contrast they showed no major changes in cells treated with the classical mitochondrial poisons antimycin or 2,4-DNP. We also measured citrate levels after ML316 treatment in our resistant mutants. In cells expressing the Mir1 N184T variant or in cells resistant due to loss of cytochrome oxidase activity (*cox4 $\Delta$* ), there was no significant increase in citrate levels (Fig. 4c). At this point, we have no evidence that citrate accumulation is directly responsible for the fungicidal activity of ML316. Nevertheless, our genetic and biochemical evidence establish the dependence of this accumulation on depletion of mitochondrial phosphate in the context of ongoing electron transport. As a signature effect, distinct from that of all other mitochondrial poisons tested, it could provide a valuable point of departure in probing the mechanism(s) by which electron transport is coordinated with ATP production in mitochondria.

### ML316 inhibits azole-resistant *C. albicans* in mice

Previous characterization of ML316 pharmacokinetics revealed poor plasma stability for the compound and precluded its testing in mouse models of systemic candida infection. To overcome this limitation and investigate its antifungal potential *in vivo*, we evaluated ML316 in a well-accepted mouse model of oropharyngeal candidiasis (OPC)<sup>21,22</sup>. Mucosal candida infections are a common, often debilitating problem in a variety of clinical settings associated with inborn or acquired deficiencies of T cell-mediated immune function and are often complicated by the emergence of azole-resistance.

To test ML316, we pre-treated mice with corticosteroids to induce susceptibility and then infected them sublingually with azole-resistant *C. albicans* originally isolated from an HIV patient with recurrent OPC<sup>6</sup>. After allowing 3 days for the infection to establish, cohorts of mice were treated with fluconazole, ML316 or the combination. Fluconazole was administered systemically while ML316 was simply added to the drinking water of animals. Antifungal activity was assessed by measuring residual colony forming units (CFU) persisting on the tongue after completing 2 days of therapy. ML316 treatment decreased fungal burden by approximately 100-fold (Fig. 5a). Treatment with fluconazole alone resulted in a similar reduction in fungal burden while the combination of both dropped fungal burden by > 1000-fold.

Microscopic examination of Periodic Acid Schiff (PAS)-stained tissue sections was consistent with CFU quantitation. Fields containing fungi were selected for imaging and

presentation to demonstrate effects on morphology (Fig. 5b). Control mice had multiple, superficially destructive lesions; a few small, dystrophic lesions were seen in tissue from mice receiving either fluconazole or ML316. No lesions were identified in mice receiving combination therapy. Equally important, no histological evidence of toxicity to normal tissues from topical exposure to ML316 was seen. ML316 treatment also appeared to impair the filamentation of the *C. albicans*. The ability of fungi to switch between yeast and filamentous forms is a critical determinant of fungal virulence due to its role in tissue invasion<sup>23</sup>. Overall, results indicate that ML316 is well tolerated topically, has significant antifungal activity alone and that combination with fluconazole *in vivo* provides greater efficacy, even against a *Candida* isolate with pre-existing azole-resistance.

## Discussion

Pathogenic fungi are remarkably resilient organisms that pose a rapidly increasing threat to human health, due in large part to our limited therapeutic arsenal and their ability to cause life-threatening systemic infections in patients with impaired immune function. The most frequently isolated fungal pathogen in humans is the yeast *C. albicans*<sup>24</sup>. This organism is capable of shifting between distinct morphological states and altering its central metabolism to invade diverse niches in humans, form biofilms- and resist available antifungals<sup>25</sup>.

Mitochondria have been identified as key players in the adaptive abilities of *C. albicans* and other fungi, enabling virulence, morphogenesis and drug resistance<sup>20,26,27</sup>. Many molecular details remain to be defined, but efforts to identify novel elements and functional diversity in the electron transport chain of pathogenic fungi have been reported<sup>28</sup>. Here, we identify the compound ML316 as an inhibitor of the mitochondrial P<sub>i</sub>C Mir1. Under respiratory conditions, ML316 transforms mitochondria from enablers of drug-resistance and pathogenesis to active instigators of fungal cell death. In addition to the value of this reagent as a chemical probe enabling basic studies, our findings demonstrate that converting fungal respiration to a toxic process by impairing phosphate uptake is feasible in animals and could provide a much needed new treatment strategy.

Mitochondrial P<sub>i</sub>Cs perform a critical function in eukaryotes. Under normal conditions, most of the energy required by cells is supplied by the generation of ATP in their mitochondria. Production takes place in the mitochondrial matrix where ATP synthase generates ATP from ADP and inorganic phosphate (P<sub>i</sub>) using the electromotive force of a proton gradient sustained by the electron transport chain. Flux through this reaction is carefully controlled by the availability of its substrates, ADP and P<sub>i</sub>. In the fungus *S. cerevisiae* the P<sub>i</sub> carrier Mir1 has been shown to be essential for respiratory growth<sup>12</sup>. Here, we have shown that selective chemical inhibition of this P<sub>i</sub>C in *C. albicans* is lethal, even in standard high glucose media which allows for energy generation by fermentation.

Although P<sub>i</sub>C proteins are similar in humans and fungi, previous experiments have indicated that P<sub>i</sub> itself plays a unique role in the mitochondria of fungi. Mir1 has been identified as part of the fungal mitochondrial unspecific channel (MUC)<sup>29</sup>. In fungi, the presence of phosphate in the inner mitochondrial matrix is essential for preventing uncoupling of electron transport and loss of membrane potential due to opening of the MUC. This does not



appear to be case for mammalian mitochondria. Differences in the stimuli that inhibit and activate the opening of MUCs in plants, fungi and mammals have been reported but the physiological relevance of these differences is not yet clear<sup>30</sup>. Although inhibition of P<sub>i</sub>C by mersalyl, a non-specific organomercury compound, was critical for early experiments defining the function of P<sub>i</sub>C<sup>13,14</sup> and the MUC in purified mitochondria<sup>29</sup>, no compounds have been previously described that selectively inhibit a P<sub>i</sub>C. Discovery of ML316 opens new avenues for research in this and related aspects of mitochondrial phosphate biology because the compound is cell permeant, highly target-selective and species-specific.

The species specificity of ML316 appears due to a single amino acid difference in the fungal protein Mir1 as compared to the homologous human P<sub>i</sub>C. Surprisingly both of the fungal species we studied have homologs of *MIR1* in their genomes that encode the same single amino acid change present in the resistant allele of humans. Designated Pic2 in *S. cerevisiae*, overexpression of this second P<sub>i</sub>C in a *mir1Δ/pic2Δ* background is reported to rescue the deletion strain's growth defect on non-fermentable carbon sources and restore phosphate uptake into the mitochondrial matrix<sup>18</sup>. Interestingly, although *S. cerevisiae* has ML316-resistant Pic2 encoded in its nuclear genome, its expression imparts only partial protection against ML316 during growth in galactose. Moreover, the organism remains very sensitive to ML316 when respiration is strictly enforced by growth in glycerol. Additionally, we never recovered any mutations involving *PIC2* in our drug-resistance selection experiments.

While active on its own, ML316 was more effective when combined with an azole. Combination therapy remains a much underutilized approach for the management of fungal infections despite being routine in the treatment of bacterial infections. The phenotypic screening strategy which led to the work with ML316 reported here and previous studies by us and others suggest that a productive strategy for developing useful antifungal combinations will involve combining azoles already in widespread use with new agents targeting mitochondrial function<sup>2</sup>.

Additional medicinal chemistry will be required to address the pharmacological liabilities of ML316 and generate a true drug candidate for either topical or systemic applications. The ethyl carbamate of ML316 appears to be the primary source of instability because replacing the carbamate with a methyl group significantly increases plasma stability. Carbamates can be susceptible to metabolic hydrolysis by numerous esterases, a feature which has been exploited in the design and synthesis of pro-drugs<sup>31</sup>. Because the saliva of humans and rodents is rich in esterase activity<sup>32</sup>, most of the material we provided to mice in their drinking water was probably degraded rapidly upon intake with relatively limited mucosal exposure to active compound, especially during the animals' daytime sleep cycle when oral intake drops. Despite these limitations we demonstrated a highly significant effect against azole-resistant *C. albicans* in mice, establishing the value of Mir1 as an antifungal target. Based on insights from the limited SAR studies performed during development of ML316 as a probe, embedding its ethyl carbamate into an oxazole or similar ring systems might provide a feasible approach to overcoming its metabolic instability.

ML316 appears a poor substrate for the major drug efflux pumps. Late isolates in the *C. albicans* clinical series we studied have marked drug pump overexpression, but remained

sensitive to the compound. In culture, we identified two other mechanisms, however, by which resistance to ML316 can be acquired. Mutations that disrupt electron transport arose with relatively high frequency under growth conditions supporting fermentative metabolism. From a therapeutic perspective, these mutants should be irrelevant because they cannot respire. This defect cripples virulence by restricting nutrient utilization and impairing filamentation while concomitantly conferring extreme sensitivity to fluconazole. Another mechanism of acquired resistance, mutation of the *MIR1* target gene itself occurred with very low frequency and only arose when growth was restricted to a respiratory substrate. The recurring mutation in *MIR1* that we recovered was hypomorphic, imparting a moderate defect in cellular respiration. So, for both modes of acquired resistance identified, the development of resistance carried debilitating fitness costs. In a mammalian host, these mechanisms would greatly impair virulence, strongly disfavoring their emergence. From a broader evolutionary perspective, targeting Mir1 with ML316 is an attractive strategy because it confronts the fungus with conflicting selective pressures. Respiration is needed for survival, virulence and azole-resistance in the host, but ongoing electron transport poisons the cell. Creating such a dilemma offers a much needed approach to development of new, resistance-evasive antifungal treatment regimens.

## Online Methods

### Chemical matter

For a full description of the synthesis and purity of compounds **1**, **2** and **3** (ML316), please refer to the Molecular Libraries probe report (<https://www.ncbi.nlm.nih.gov/books/NBK143544/>). Synthesis of INZ-5 has been previously reported<sup>2</sup>. Fluconazole was obtained from Sequoia Research Products (Cat SRP01025f) with a purity of >99%. Antimycin A was purchased from Sigma (Cat A8674) as a mixture of antimycins that conforms to specifications. 2,4 DNP was purchased from Sigma (D198501) purity >98%. Amphotericin B was purchased from Sigma (A2411) purity ~80% (suitable for tissue culture). Rotenone was also from Sigma (R8875) purity 95–98%.

### Yeast Strains and human cell lines

The fluconazole-resistant *C. albicans* series CaCi-2, CaCi-8, CaCi-12, CaCi-15 and CaCi-17 was obtained from Ted White.<sup>6</sup> Other resistant *C. albicans* pairs were provided by Aaron Mitchell.<sup>33</sup> Deletions mutants  $\Delta rip1/\Delta rip1$  and  $\Delta cox4/\Delta cox4$  were a gift from Suzanne Nobel<sup>34</sup>. Supplementary Table 1 contains the source information for other strains included therein. The human cell lines HepG2 and 293T were purchased from the American Type Culture collection (ATCC) and confirmed negative for mycoplasma contamination by PCR-based testing.

### Antifungal susceptibility testing

The anti-proliferative activity of compounds in media supplemented with glucose, galactose or glycerol was measured using standard antifungal susceptibility protocols<sup>35</sup>. After 24 hours the optical density at 600 nm (OD<sub>600</sub>) was read in 96-well format using an Envision plate reader. To assess the fungicidal activity of compounds, cultures growing in 96-well liquid format, were re-suspended with a multichannel pipette and spotted to fresh, drug-free

yeast extract peptone dextrose (YPD) plate using a metal frogger. Plates were then incubated at 30 °C for an additional 2 days before image capture. Checkerboard analysis was performed as previously described<sup>7</sup>.

### Suppressor Mutant Isolation and Identification

*C. albicans* strains SC5314 or CaCi-2 were grown to saturation overnight in Difco Yeast-Nitrogen-Base with complete amino acid supplementation (YNB-CSM) with 2% glucose, pelleted by centrifugation, and re-suspended in phosphate-buffered saline. Approximately  $10^7$  cells were plated onto agar medium formulated with ML316 (5  $\mu$ M) in YNB-CSM and either 2% glucose or 2% glycerol as the carbon source. After 5 days, colonies that emerged were re-streaked on the same media to isolate single colonies. These colonies were expanded in liquid culture for preparation of genomic DNA using a Yeastar genomic DNA extraction kit (Zymo Research). Genome sequencing and bio-informatic analysis was performed as described previously.<sup>36</sup>

### Metabolite Profiling

An overnight culture of *C. albicans* was diluted into YNB-CSM-2% glucose media at an OD<sup>600</sup> of 0.25, grown for 3hr to mid-log phase, and then split into parallel 5 mL cultures for treatment with compounds (DMSO, 20 $\mu$ M rotenone, 1 $\mu$ M antimycin, 5mM potassium cyanide, 20 $\mu$ M oligomycin, 25  $\mu$ g/mL 2,4-dinitrophenol, 32  $\mu$ M FCCP, 2.5  $\mu$ M ML316). After growth with compounds for the indicated time intervals, cultures were pelleted, washed once in PBS, and frozen in liquid nitrogen. Polar metabolites were extracted by re-suspending cells in 600  $\mu$ L methanol, 300  $\mu$ L water, and 400  $\mu$ L chloroform, and adding 100  $\mu$ L of glass beads before vortexing for 60 seconds. Samples were then centrifuged for 10 minutes at 13,000g, and the supernatant (polar) layer was moved to a new microcentrifuge tube, and evaporated by Speedvac. Samples were then subjected to LC-MS/MS profiling on a Thermo Orbitrap platform, as described previously.<sup>37</sup>

### Phosphate Swelling Assays

*C. albicans* strains were grown in yeast extract-peptone-glycerol (3% w/v) media (YPG) at 30° C with shaking. Intact mitochondria were isolated using a standard procedure for *S. cerevisiae* as previously published<sup>38</sup>. The phosphate swelling assays were performed as described<sup>15</sup> with the several modifications. To assess turbidity changes induced by addition of specific anions in the presence of test compounds, the cassette attachment of a MultiSkán Go instrument was used (ThermoFisher). The instrument was programmed for a kinetic run at 30° C, monitoring OD 544 and reading every 10 seconds. To start the experiment 40  $\mu$ l of mitochondria (100  $\mu$ g total protein) was added to 1 ml of salt solution in a disposable cuvette, vortexed and the run started. Prior to reading, 10  $\mu$ M ML316 or an equivalent amount of DMSO was added to 100  $\mu$ g of mitochondria on ice. Three replicates were run for each condition and the experiment repeated in full once.

### Mitochondrial Oxygen Consumption

*C. albicans* strains were pre-grown in 3% glycerol YNB-CSM media at 30° C. The oxygen consumption of exponentially growing cells was measured at 30° C with an Oxytherm

oxygraph (Hansatech Instruments, Norfolk, England). Four OD<sub>600</sub> units of cells were re-suspended in 2 ml of growth media and then split into two aliquots. Ten minutes prior to measurement, 10  $\mu$ M ML316 was added to one aliquot and an equivalent volume of vehicle (1  $\mu$ l DMSO) to the other aliquot. Mitochondrial oxygen consumption (MOC) rate was allowed to stabilize for a short interval then measured over three equal time periods and averaged. 50  $\mu$ M antimycin was then added and the rate measured again over three time windows and averaged. The average antimycin-treated rate was subtracted from the non-antimycin rate for each experimental condition tested to calculate MOC rate.

### Oropharyngeal candidiasis model

Female, 4–6 week old BALB/c mice were immunosuppressed with cortisone acetate as previously described.<sup>21</sup> Animals were subsequently inoculated sublingually with *C. albicans* strain CaCi-2. To do so, animals were sedated with ketamine and xylazine, after which calcium alginate swabs that had been soaked in Hanks' balanced salt solution containing 10<sup>6</sup> *C. albicans* cells/ml were placed sublingually for 90 min. After 3 days to allow establishment of infection, cages of mice were randomly assigned to experimental groups and treatment with antifungal compounds begun. No blinding was performed. Cohort size was determined based on prior experience with this animal model. ML316 (3.2  $\mu$ M) was administered *ad lib* in drinking water supplemented with sucrose (1% w/v) to increase palatability. To aid in formulation, a concentrated stock solution of ML316 was prepared at 1 mg/ml in PEG400, stored at –20 °C until use and diluted into fresh sucrose-containing water daily. Control mice received sucrose-containing drinking water supplemented with an equal volume of PEG400 vehicle (.001% v/v). Fluconazole was administered intraperitoneally at 10 mg/kg/d. Mice were euthanized five days after fungal infection and the tongues were divided longitudinally. One half was weighed and homogenized in PBS for quantitative culture. The other half was fixed in zinc-buffered formalin and embedded in paraffin, after which thin sections were cut and stained with Periodic acid-Schiff (PAS). All treatment groups consisted of 8 animals except the fluconazole group which had 7. All animal experimentation was performed under a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the Los Angeles Biomedical Research Institute.

### Statistics

GraphPad Prism 7 was used to generate all statistics reported. Replicate numbers (n values) are provided in the relevant figure legends. The t-tests reported in Figure 3b are unpaired, two-tailed, parametric values. The exact p-values for the comparisons shown are *MIR1* DMSO versus *MIR1* ML316, p=0.0248, *MIR1* DMSO versus *mir1R* DMSO, p=0.0751, and *mir1R* DMSO versus *mir1R* ML316, p=0.3227. The Mann-Whitney tests reported in Figure 5 are two tailed, unpaired, non-parametric calculations. The exact p-value for comparison of ML316 and fluconazole reported as not significant is p=0.2949. All other p-values are indicated in the figure.

### Data Availability Statement

Genomic sequence data presented in this study are available for download from NCBI bioproject at <http://www.ncbi.nlm.nih.gov/bioproject/388652> (Bioproject accession number

PRJNA388652), and at the NCBI SRA at <http://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP108351> (accession number SRP108351)

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Thanks to M. Vander Heiden, V. Mootha and R. Mazitschek for helpful discussions. We also thank the Whitehead GTC, especially J. Love, T. Volkert, and S. Gupta for assistance with genome sequencing. We thank E. Freinkman (Whitehead Metabolomics Core) for assistance with metabolite profiling. S.L. was an HHMI investigator. Additional support was provided by NIH grants R01DE022600 (S.G.F.), U54HG005032-1 (Stuart Schreiber, Broad Institute), R03MH08645601 (S.L.) and R01AI120958-01A1 (L.W.). A postdoctoral fellowship from the American Cancer Society supported L.B.S. while B.M.V. was supported in part by an NSF graduate research fellowship and the Mathers Foundation.

## References

1. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. *Science*. 2005; 309:2185–9. [PubMed: 16195452]
2. Vincent BM, et al. A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence, Prevents the Evolution of Drug Resistance. *Cell Chem. Biol.* 2016; 23:978–992. [PubMed: 27524297]
3. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries for their exclusion in bioassays. *J. Med. Chem.* 2010; 53:2719–2740. [PubMed: 20131845]
4. Tran C, et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. *Science* (80-). 2009; 324:787–790.
5. Strijbis K, Distel B. Intracellular acetyl unit transport in fungal carbon metabolism. *Eukaryot. Cell.* 2010; 9:1809–1815. [PubMed: 20889721]
6. White TC. Increased mRNA Levels of *ERG16*, *CDR*, and *MDR1* Correlate with Increases in Azole Resistance in *Candida albicans* Isolates from a Patient Infected with Human Immunodeficiency Virus. *Microbiology*. 1997; 41:1482–1487.
7. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test, checkerboard methods of antimicrobial combinations against *Brucella melitensis*. *J. Clin. Microbiol.* 2005; 43:140–143. [PubMed: 15634962]
8. Ford CB, et al. The evolution of drug resistance in clinical isolates of *Candida albicans*. *Elife*. 2015; 4:e00662. [PubMed: 25646566]
9. Perea S, et al. Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in *Candida albicans* Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients Prevalence of Molecular Mechanisms of Resistance. *Antimicrob. Agents Chemother.* 2001; 45:2676–2684. [PubMed: 11557454]
10. Clancy CJ, Nguyen MH. Emergence of *Candida auris*: An international call to arms. *Clin. Infect. Dis.* 2017; 64:141–143. [PubMed: 27989986]
11. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the crabtree effect: Replacing media glucose with galactose increases susceptibility of *hepG2* cells to mitochondrial toxicants. *Toxicol. Sci.* 2007; 97:539–547. [PubMed: 17361016]
12. Murakami H, Blobel G, Pain D. Isolation and characterization of the gene for a yeast mitochondrial import receptor. *Nature*. 1990; 347:488–91. [PubMed: 2170848]
13. Tyler DD. Evidence of a phosphate-transporter system in the inner membrane of isolated mitochondria. *Biochem. J.* 1969; 111:665–678. [PubMed: 5783467]
14. Phelps A, Schobert CT, Wohlrab H, Ptp Y, *Saccharomyces P.* Cloning and Characterization of the Mitochondrial Phosphate Transport Protein Gene from the Yeast. *Biochemistry*. 1991:248–252. [PubMed: 1840493]

15. Zara V, et al. Yeast mitochondria lacking the phosphate carrier/p32 are blocked in phosphate transport but can import preproteins after regeneration of a membrane potential. *Mol. Cell. Biol.* 1996; 16:6524–6531. [PubMed: 8887681]
16. Seifert EL, Ligeti E, Mayr JA, Sondheimer N, Hajnoczky G. The mitochondrial phosphate carrier: Role in oxidative metabolism, calcium handling mitochondrial disease. *Biochem. Biophys. Res. Commun.* 2015; 464:369–375. [PubMed: 26091567]
17. Giaever G, et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. *Nat. Genet.* 1999; 21:278–283. [PubMed: 10080179]
18. Hamel P, et al. Redundancy in the function of mitochondrial phosphate transport in *Saccharomyces cerevisiae*, *Arabidopsis thaliana*. *Mol. Microbiol.* 2004; 51:307–317. [PubMed: 14756774]
19. Lemaire C, Robineau S, Netter P. Molecular and biochemical analysis of *Saccharomyces cerevisiae* *cox1* mutants. *Curr. Genet.* 1998; 34:138–45. [PubMed: 9724417]
20. Sun N, et al. Azole susceptibility transcriptome profiling in *Candida albicans* mitochondrial electron transport chain complex I mutants. *Antimicrob. Agents Chemother.* 2013; 57:532–542. [PubMed: 23147730]
21. Solis NV, Filler SG. Mouse model of oropharyngeal candidiasis. *Nat. Protoc.* 2012; 7:637–42. [PubMed: 22402633]
22. Swidergall M, Filler SG. Oropharyngeal Candidiasis: Fungal Invasion and Epithelial Cell Responses. *PLOS Pathog.* 2017; 13:e1006056. [PubMed: 28081240]
23. Shapiro RS, Robbins N, Cowen LE. Regulatory Circuitry Governing Fungal Development, Drug Resistance, Disease. *Microbiol. Mol. Biol. Rev.* 2011; 75:213–267. [PubMed: 21646428]
24. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. *Clin. Microbiol. Rev.* 2007; 20:133–163. [PubMed: 17223626]
25. Noble SM, Gianetti BA, Witchley JN. *Candida albicans* cell-type switching, functional plasticity in the mammalian host. *Nat. Rev. Microbiol.* 2016; 15:96–108. [PubMed: 27867199]
26. Shingu-Vazquez M, Traven A. Mitochondria, fungal pathogenesis: Drug tolerance, virulence, potential for antifungal therapy. *Eukaryot. Cell.* 2011; 10:1376–1383. [PubMed: 21926328]
27. Grahl N, et al. Mitochondrial Activity *Cyr1* Are Key Regulators of *Ras1* Activation of *C. albicans* Virulence Pathways. *PLoS Pathog.* 2015; 11:1–34.
28. Li D, She X, Calderone R. Functional diversity of complex I subunits in *Candida albicans* mitochondria. *Curr. Genet.* 2016; 62:87–95. [PubMed: 26373419]
29. Gutiérrez-Aguilar M, Pérez-Martínez X, Chávez E, Uribe-Carvajal S. In the phosphate carrier is a component of the mitochondrial unselective channel. *Arch. Biochem. Biophys.* 2010; 494:184–191. [PubMed: 19995548]
30. Cortés P, Castrejón V, Sampedro JG, Uribe S. Interactions of arsenate, sulfate, phosphate with yeast mitochondria. *Biochim. Biophys. Acta - Bioenerg.* 2000; 1456:67–76.
31. Ghosh AK, Brindisi M. Organic Carbamates in Drug Design, Medicinal Chemistry. *J. Med. Chem.* 2015; 58:2895–2940. [PubMed: 25565044]
32. Yoshimura Y, Morishita M, Moni M. Zymograms and Histochemistry of Non-specific Esterase in the Salivary Glands. *Histochemie.* 1969; 18:302–313. [PubMed: 4187597]
33. Bruno VM, Mitchell AP. Regulation of azole drug susceptibility by *Candida albicans* protein kinase CK2. *Mol. Microbiol.* 2005; 56:559–573. [PubMed: 15813744]
34. Noble SM, French S, Kohn LA, Chen V, Johnson AD. Systematic screens of a *Candida albicans* homozygous deletion library decouple morphogenetic switching, pathogenicity. *Nat. Genet.* 2010; 42:590–598. [PubMed: 20543849]
35. Xie JL, Singh-babak SD, Cowen LE. Minimum Inhibitory Concentration (MIC) Assay for Antifungal Drugs. *Bioprotocol.* 2012; 2:1–6.
36. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B. *PLoS Biol.* 2013; 11
37. Birsoy K, et al. An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis. *Cell.* 2015; 162:540–551. [PubMed: 26232224]


38. Morizono H, Woolston JE, Colombini M, Tuchman M. The use of yeast mitochondria to study the properties of wild-type and mutant human mitochondrial ornithine transporter. *Mol. Genet. Metab.* 2005; 86:431–440. [PubMed: 16256388]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




**Figure 1. ML316 is a potent, highly selective fungicide**

(a) Structures of ML316, original screen hit and inactive analog. Minimal inhibitory concentrations (MIC) are indicated for the *C. albicans* strain CaCi-2. For ML316  $1 \mu\text{M} = 0.35 \mu\text{g/ml}$ . (b) Glucose-grown *S. cerevisiae* are not sensitive to ML316. Standard antifungal susceptibility testing was performed in YNB-CSM media with either glucose (Glu, 2% w/v) or glycerol (Gly, 2% w/v) as the carbon source. Optical densities were measured after 24 h at 30 °C and standardized to drug-free controls. The mean of three independent wells is shown. Error bars: s.e.m. (c) ML316 reduces growth of fluconazole-resistant *C. albicans* (strain CaCi-2), an effect that is increased by fluconazole (Flu). Assays in the presence or



absence of Flu (8  $\mu\text{g/ml}$ ) were performed as in (b) except growth medium was RPMI supplemented with 2% glucose. The mean of two independent wells is shown. (d) ML316 inhibits growth of increasingly azole-resistant *C. albicans* strains isolated from the same HIV-infected patient over a 2-year interval. Strain designations are indicated to the left of the heat maps. Sensitivity testing was performed as in (c). The mean of results from two independent experiments is depicted. (e) ML316 is not cytotoxic to human cell lines under respiratory conditions. Viability was assessed by standard resazurin dye-reduction assay after 72 h growth at 37 °C in DMEM supplemented with galactose (10 mM) and dialyzed fetal bovine serum (10%). Data points depict the mean of measurements from 2 independent wells for each condition tested. (f) ML316 is fungicidal. A standard growth assay was performed as in (c) at either 30 or 37 °C. After 24 h, aliquots were spotted onto YPD agar plates and cultured for an additional 2 days. Scale bar = 10 mm. Data in (c), (e), and (f) are derived from one representative experiment. Two independent experiments yielding similar results were performed.



**Figure 2. Genetic evidence for Mir1 as primary target of ML316**

(a) ML316-sensitivity is correlated with *MIR1* gene dosage and mutation status. Antifungal susceptibility testing with ML316 was performed using wild type and genetically modified *C. albicans* strains. Relative growth as monitored by OD<sub>600</sub> was normalized to untreated control for each strain and is displayed in heat map format. Data represent the mean of results from two independent experiments. (b and c) ML316 treatment phenocopies the deletion of *MIR1* in *S. cerevisiae*. Change in optical density over time as a measure of growth was monitored in liquid cultures of wild type *S. cerevisiae* and the indicated mutant strains. Assays were performed in (b) glucose- or (c) galactose-supplemented synthetic


media with vehicle (DMSO) or ML316 (500nM) added as indicated. Results are from one of two independent experiments. The mean of measurements from 4 independent wells is depicted.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 3. Biochemical confirmation of ML316 as an inhibitor of Mir1**


(a) ML316 inhibits phosphate-induced swelling and disruption of purified *C. albicans* mitochondria. The integrity of purified mitochondria isolated from strains expressing an additional copy of either the wild type (*MIR1*) or drug-resistant (*mir1R*) gene version was monitored by optical density (OD). The effect of various inorganic anions on mitochondrial integrity in the presence or absence of ML316 (5  $\mu$ M) is presented. Buffer alone served as baseline. Initial measurements were acquired approximately 10 seconds after addition of mitochondria to each reaction. Three independent aliquots of mitochondria were assayed for each condition. The entire experiment was performed twice. The mean and s.d. of

measurements from one of these experiments is shown. **(b)** ML316 reduces the mitochondrial oxygen consumption (MOC) of *C. albicans* expressing an additional copy of *MIR1* but not *mir1R*. The MOC rate of *C. albicans* strains grown in glycerol was measured 10 min after addition of ML316 (10  $\mu$ M) or vehicle control (DMSO). Three independent aliquots of mitochondria were assayed in each of two independent experiments. The mean of one is shown. Error bars: s.e.m. \*  $p < 0.025$  compared to DMSO-treated control (unpaired, two-tailed, parametric t-test).



**Figure 4. ML316 renders respiration toxic and increases citrate levels**

(a) *C. albicans* strain CaCi2 with genetic deletion of mitochondrial *COX1* are resistant to ML316 but are unable to respire or grow in the presence of fluconazole. Serial dilutions of CaCi-2 or CaCi-2 *cox1* were spotted on media with carbon sources supporting fermentation (glucose) or enforcing respiration (glycerol) in presence or absence of ML316 (5  $\mu$ M) or Flu (16  $\mu$ M) as indicated. Plates were imaged after 2 days at 30  $^{\circ}$ C. (b) Citrate levels increase dramatically upon treatment with ML316 but not with other mitochondrial poisons. LC/MS was used to measure levels of citrate in *C. albicans* grown in synthetic defined media (2% glucose) following 30 or 60 min exposure to ML316 (5  $\mu$ M), Antimycin (1  $\mu$ M), or 2,4-dinitrophenol (25  $\mu$ g/mL). All values were normalized to the mean for DMSO-treated samples. Values represent the mean and s.e.m. of determinations from 2 independent experiments, each consisting of 3 independent cultures. (c) ML316 increases citrate levels in wild-type *Candida* but not in ML316-resistant mutant strains expressing either *mir1R* or carrying a deletion of *COX4*. Citrate levels were determined by LC/MS in strains growing in glucose after 60 min exposure to ML316 (5  $\mu$ M). In the genotypes indicated on the x-axis, “V” denotes empty vector control. Citrate levels were normalized to the mean of wild type, DMSO-treated samples. Mean and s.e.m. from 2 independent experiments each consisting of 3 independent cultures are shown.



**Figure 5. ML316 is active against azole-resistant *C. albicans* in mice**

(a) Mice were treated with corticosteroids to induce susceptibility and infected sublingually with strain CaCi-2. Three days later, they were randomly assigned to treatment as indicated (n=8/ group except fluconazole (Flu) n=7). ML316 was added to drinking water (2.85  $\mu$ M ML316/ 1% w/v sucrose) while Flu was administered intraperitoneally (10 mg/kg/day). Antifungal activity was assessed by measuring residual colony forming units (CFU) persisting on the tongue after completing 2 days of therapy. Mean and s.d. are displayed. The statistical significance of differences between treatment groups was determined by Mann Whitney test (unpaired, 2 tailed, non-parametric). P values are indicated above the

relevant comparisons (Flu vs ML316; not significant). **(b)** Photomicrographs of PAS-stained tissue sections to assess fungal morphology are presented. Arrow heads indicate fungal foci which appear dark pink against the lighter staining of the keratinized papillae of the host tongue.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript